中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 3
Mar.  2008
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2008  >  24(3): 172-174

乙型肝炎病毒BCP变异与拉米夫定治疗后HBVDNA反弹关系的研究

Research funding:

 

  • Published Date: 2008-03-20
    Abstract
  • Objective To investigate the relationship of Hepatitis B virus BCP mutation in the hepatitis B virus (HBV) genome and HBVDNA rebound after with lamivudine therapy.Methods With inspected twenty-seven patients (therapy group, HBVDNA>104 copie4/ml) with HBVDNA rebound after respond to virus beyond 6 months with infecting hepatitis B received lamivudine (100mg/day) oral application for at least 12 months and nineteen patients (control group) with infecting hepatitis B without treated with the drug of antivirus, we have examined mutation in the Basal Core Promoter (BCP) of the Hepatitis B virus (HBV) of two group by PCR-gene sequence analysis.Results 1.The rate of BCP (A1762T+G1764A) mutations were 44.44% (12/27) in HBVDNA-negative group beyond control group 6.32% (5/19) , but it has not statistic difference (P>0.05) .2.In the therapy group, BCP (A1762T+G1764A) mutation were not examined in four patients before therapy, but it were examined in two patients after therapy.Conclusion BCP (T1762/A1764) mutation may be associated with HBVDNA rebound after lamivudine therapy.

     

    • FullText(HTML)
    • References(8)
  • [1] 中华医学会.病毒性肝炎防治方案[J].中西医结合肝病杂志, 2001, 11 (1) ∶56-60.
    [2]Liaw YF, Leung NW, Chang TT, et al.Effects of extended lamivu-dine therapy in Asian patients with chronic hepatitis B[J].Gastroen-terology, 2000, 119 (1) ∶172-180.
    [3]Leung NW, Lai CL, Chang LR, et al.Extended lamivudine treat-ment in patients with chronic hepatitis B enhances hepatitis B e anti-gen seroconversion rates:results after3 years of therapy[J].Hepatol-ogy, 2001, 33 (6) ∶1527-1532.
    [4]Lok AS, McMahon BJ.Chronic hepatitis B:Update of Recommenda-tions[J].Hepatology, 2004, 39 (3) ∶857-861.
    [5]Stuyver LJ, Locarnini SA, Lok A, et al.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase re-gion[J].Hepatology, 2001, 33 (3) ∶751-757.
    [6]Laras A, Koskinas J, Hadziyannaia SJ.In vivo suppression of pre-core mRNA synthesis is associated with mutations in the hepatitis Bvirus core promoter[J].Virology, 2002, 30 (1) ∶86-96.
    [7]Chen CH, Lee CM, Lu SN, et al.Comparison of sequence changesof precore and core promoter regions in HBeAg-positive chronichepatitis B patients with and without HBeAg clearance in lamivudinetherapy[J].J Hepatol, 2006, 44 (1) ∶76-82.
    [8]Tacke F, Gehrke C, Luedde T, et al.Basal core promoter and pre-core mutations in the hepatitis B virus genome enhance replication ef-ficacy of Lamivudine-resistant mutants[J].J Virol, 2004, 78 (16) ∶8524-35.
    • Relative Articles

  • Relative Articles

    [1]Liu Cheng, Mu YongPing, Yang ZongGuo, Chen XiaoRong, Lu YunFei, Xu QingNian. Predictive value of HBcrAg for lamivudine resistance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(11): 820-823. doi: 10.3969/j.issn.1001-5256.2013.11.005
    [2]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [7]Li Jun, Chen XinYue, Zhao Hong, Yu YanYan, Si ChongWen, Han ZhongHou, Zhang WenJin, Chen YuPing, Chen Yong, Wang GuiQiang, Yu Min, Gong WeiBo, Xu JingHang, Wang Jun, Lin XiaoHong, Li XueYing. The relationship of hepatitis B virus genotypes and efficacy of lamivudine and interferon alpha 2b in the treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(3): 169-171.
    [8]Zhan GuoQing, Jiang Shan, Zheng SanJu, Zhu Lin. Observations on dynamic changes of high level hepatitis B virus during sequential therapy of chronic hepatitis B with IFN α-1b and lamivudine.[J]. Journal of Clinical Hepatology, 2008, 24(1): 19-21.
    [13]Gu QiangYe, Chen HeMin. Therapeutic efficacy of combined application of Lamivudine and Ganluoxinpills in treating chronic hepatitis B and its in fluence on YMDD motif[J]. Journal of Clinical Hepatology, 2005, 21(2): 79-80.
    [15]Tian DeYing, Xu Dong, Xing MingYou, Guo Wei, Song PeiHui. Research on relationship of HBV YMDD mutation and lamivudine resistance.[J]. Journal of Clinical Hepatology, 2004, 20(3): 161-162.
    [17]Zhao Wei, Wan JianMin, Liu Wei, Liu QuanJun, Zhang Lin, Zhang HanRong, Liu XinYu, Zhou ZhenXian. Detection and identification of emergence of HBV YMDD motif mutation during lamivudine treatment by hybridization to an oligonucleotide array[J]. Journal of Clinical Hepatology, 2003, 19(3): 178-180.
    [20]Wang Jun, Li YongFu, Hu QiaoLing, Zhang Liu. Short-term effect of Lamivudine with Gan Bi Tuo treatment in patients with hepatits B[J]. Journal of Clinical Hepatology, 2001, 17(3): 167-168.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 8.8 %FULLTEXT: 8.8 %META: 89.4 %META: 89.4 %PDF: 1.8 %PDF: 1.8 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.2 %其他: 3.2 %China: 0.3 %China: 0.3 %United States: 0.9 %United States: 0.9 %上海: 3.8 %上海: 3.8 %北京: 9.4 %北京: 9.4 %南宁: 0.3 %南宁: 0.3 %南昌: 0.3 %南昌: 0.3 %吉林: 0.6 %吉林: 0.6 %哥伦布: 0.6 %哥伦布: 0.6 %张家口: 1.5 %张家口: 1.5 %杭州: 0.6 %杭州: 0.6 %武汉: 0.3 %武汉: 0.3 %深圳: 0.3 %深圳: 0.3 %石家庄: 0.3 %石家庄: 0.3 %芒廷维尤: 34.7 %芒廷维尤: 34.7 %莫斯科: 1.8 %莫斯科: 1.8 %西宁: 40.6 %西宁: 40.6 %长春: 0.6 %长春: 0.6 %其他ChinaUnited States上海北京南宁南昌吉林哥伦布张家口杭州武汉深圳石家庄芒廷维尤莫斯科西宁长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2287) PDF downloads(839) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3590]YesterdayPV[6562]TodayIP[1415]TodayPV[2061]Online[181]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return